- Home
- CGEN vs BARK Comparison
CGEN vs BARK Comparison
Compare CGEN & BARK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGEN
- BARK
- Stock Information
- Founded
- CGEN 1993
- BARK 2011
- Country
- CGEN Israel
- BARK United States
- Employees
- CGEN N/A
- BARK N/A
- Industry
- CGEN Biotechnology: Biological Products (No Diagnostic Substances)
- BARK Department/Specialty Retail Stores
- Sector
- CGEN Health Care
- BARK Consumer Discretionary
- Exchange
- CGEN Nasdaq
- BARK Nasdaq
- Market Cap
- CGEN 125.3M
- BARK 146.0M
- IPO Year
- CGEN 2000
- BARK N/A
- Fundamental
- Price
- CGEN $1.65
- BARK $0.74
- Analyst Decision
- CGEN
- BARK Strong Buy
- Analyst Count
- CGEN 0
- BARK 3
- Target Price
- CGEN N/A
- BARK $2.50
- AVG Volume (30 Days)
- CGEN 324.9K
- BARK 1.1M
- Earning Date
- CGEN 11-10-2025
- BARK 11-10-2025
- Dividend Yield
- CGEN N/A
- BARK N/A
- EPS Growth
- CGEN N/A
- BARK N/A
- EPS
- CGEN N/A
- BARK N/A
- Revenue
- CGEN $6,903,000.00
- BARK $451,690,000.00
- Revenue This Year
- CGEN N/A
- BARK N/A
- Revenue Next Year
- CGEN $208.08
- BARK $6.25
- P/E Ratio
- CGEN N/A
- BARK N/A
- Revenue Growth
- CGEN N/A
- BARK N/A
- 52 Week Low
- CGEN $1.13
- BARK $0.73
- 52 Week High
- CGEN $2.66
- BARK $2.56
- Technical
- Relative Strength Index (RSI)
- CGEN 46.42
- BARK 37.72
- Support Level
- CGEN $1.54
- BARK $0.74
- Resistance Level
- CGEN $1.79
- BARK $0.84
- Average True Range (ATR)
- CGEN 0.11
- BARK 0.07
- MACD
- CGEN -0.01
- BARK -0.01
- Stochastic Oscillator
- CGEN 34.62
- BARK 2.79
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.
About BARK BARK Inc.
BARK Inc is a vertically integrated, omnichannel brand serving dogs across two key categories: toys & accessories and consumables. It serves dogs nationwide with monthly subscription services, BarkBox and Super Chewer; e-commerce experience on BarkShop.com; custom collections via its retail partner network, including Target and Amazon; wellness products that meet dogs' needs with BARK Bright; and a personalized meal delivery service for dogs BARK Eats. The company's reportable segments are; Direct to Consumer (D2C), and Commerce. The majority of its revenue is generated from the Direct to Consumer segment which derives revenue from the sale of toys & accessories and consumables through BarkBox, Super Chewer, and the company's consumables website.